Catalyst
Slingshot members are tracking this event:
Portola (PTLA) Expects US Launch in August 2017 for Betrixaban in Prevention of VTE in Acute Medically Ill Patients
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 05, 2017
Occurred Source:
http://investors.portola.com/phoenix.zhtml?c=198136&p=irol-newsArticle&ID=2298299
Related Projects
- Diving into Portola's strategy laid out in the NEJM for obtaining FDA approval of Betrixaban in preventing VTE in Acute Medically Ill patients after APEX failed. PTLA Executed On: Feb 14, 2017 at 12:00 PM EST
Related Keywords
Us Launch, Betrixaban, Vte, Acute Medically Ill Patients
